MELD: the holy grail of organ allocation?

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 60, Issue 1, Pages (January 2014)
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
The impact of hepatitis E in the liver transplant setting
Evangelos Cholongitas, George V. Papatheodoridis, Andrew K. Burroughs 
Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 
Inflammasomes in liver diseases
Volume 50, Issue 4, Pages (April 2009)
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
m-TOR inhibitors: What role in liver transplantation?
MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis  Wichit Srikureja,
Reply to: “Serum HBV pgRNA as a clinical marker for cccDNA activity”
m-TOR inhibitors: What role in liver transplantation?
Volume 68, Issue 5, Pages (May 2018)
Volume 61, Issue 6, Pages (December 2014)
Volume 51, Issue 6, Pages (December 2009)
The impact of hepatitis E in the liver transplant setting
Reactive oxygen species in the normal and acutely injured liver
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Immigration and viral hepatitis
Marcus-Alexander Wörns, Peter Robert Galle  Journal of Hepatology 
Volume 66, Issue 1, Pages 1-4 (January 2017)
Living donor liver transplantation: is the hype over?
What lessons have we learned in pediatric liver transplantation?
Reply to: “DCD consensus and futility in liver transplantation”
The place of downstaging for hepatocellular carcinoma
Mauro Bernardi, Stefano Gitto, Maurizio Biselli  Journal of Hepatology 
Reply to: “Low free T3 levels are related to early mortality in patients with decompensated cirrhosis and acute-on chronic liver failure”  Rakhi Maiwall,
Evangelos Cholongitas, George V. Papatheodoridis, Andrew K. Burroughs 
Volume 68, Issue 1, Pages (January 2018)
Hepatitis C core protein – The “core” of immune deception?
Volume 124, Issue 1, Pages (January 2003)
Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel 
Volume 70, Issue 1, Pages (January 2019)
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Volume 62, Issue 3, Pages (March 2015)
Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore 
Volume 55, Issue 2, Pages (August 2011)
Who should get a liver graft?
EASL Clinical Practice Guidelines: Wilson’s disease
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
Age and liver transplantation
Volume 57, Issue 5, Pages (November 2012)
Volume 50, Issue 4, Pages (April 2009)
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Immigration and viral hepatitis
Evolution of liver transplantation for hepatocellular carcinoma
Clinical Practice Guidelines of the European Association for the study of the Liver – Advancing methodology but preserving practicability  Markus Cornberg,
Global burden of alcoholic liver diseases
HCV targeting of patients with cirrhosis
The impact of intestinal microflora on serum bilirubin levels
Volume 63, Issue 1, Pages (July 2015)
Familial amyloidosis: Great progress for an orphan disease
The use of hemospray in portal hypertensive bleeding; a case series
Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice  Paolo Angeli, Pere Gines 
m-TOR inhibitors: What role in liver transplantation?
J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer 
New trials and results in systemic treatment of HCC
Liver transplantation in children
Pathogenesis of cholestatic hepatitis C
Donor-recipient matching: Myths and realities
Chimeric mouse model of hepatitis B virus infection
Genetics of hepatocellular carcinoma: The next generation
MELD: the holy grail of organ allocation?
Thierry Gustot, Rajiv Jalan  Journal of Hepatology 
Fondaparinux (Arixtra∗) hepatotoxicity in a 6 year-old child
Reversion of disease manifestations after HCV eradication
Presentation transcript:

MELD: the holy grail of organ allocation? Richard B. Freeman  Journal of Hepatology  Volume 42, Issue 1, Pages 16-20 (January 2005) DOI: 10.1016/j.jhep.2004.11.002 Copyright © 2004 European Association for the Study of the Liver Terms and Conditions

Fig. 1 MELD score equation used for liver allocation in the US after 27 February, 2002. *Laboratory values are adjusted to 1.0 to avoid negative values that would result in a negative MELD score. Journal of Hepatology 2005 42, 16-20DOI: (10.1016/j.jhep.2004.11.002) Copyright © 2004 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Comparison of average number of days alive for MELD score ranges. For patients with MELD scores <15 on average, they have a higher number of survival days without a transplant. For all other MELD score ranges ≥15, patients accrue more survival days with a transplant. From Wolfe, R.A., presented at the Evolving Concepts in Liver Allocation In the MELD/PELD Era National Conference, Washington, D.C., 9 December 2003. Journal of Hepatology 2005 42, 16-20DOI: (10.1016/j.jhep.2004.11.002) Copyright © 2004 European Association for the Study of the Liver Terms and Conditions